ZA201604560B - Heterocyclic modulators of lipid synthesis for use against cancer and viral infections - Google Patents

Heterocyclic modulators of lipid synthesis for use against cancer and viral infections

Info

Publication number
ZA201604560B
ZA201604560B ZA2016/04560A ZA201604560A ZA201604560B ZA 201604560 B ZA201604560 B ZA 201604560B ZA 2016/04560 A ZA2016/04560 A ZA 2016/04560A ZA 201604560 A ZA201604560 A ZA 201604560A ZA 201604560 B ZA201604560 B ZA 201604560B
Authority
ZA
South Africa
Prior art keywords
viral infections
against cancer
use against
lipid synthesis
heterocyclic modulators
Prior art date
Application number
ZA2016/04560A
Other languages
English (en)
Inventor
Allan S Wagman
Russell J Johnson
Cristiana A Zaharia
Haiying Cai
Lily W Hu
Greg Duke
Yamini Ohol
Timothy Heuer
Marie O'farrell
Original Assignee
3 V Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3 V Biosciences Inc filed Critical 3 V Biosciences Inc
Publication of ZA201604560B publication Critical patent/ZA201604560B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA2016/04560A 2014-01-07 2016-07-05 Heterocyclic modulators of lipid synthesis for use against cancer and viral infections ZA201604560B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461924520P 2014-01-07 2014-01-07
PCT/US2015/010459 WO2015105860A1 (en) 2014-01-07 2015-01-07 Heterocyclic modulators of lipid synthesis for use against cancer and viral infections

Publications (1)

Publication Number Publication Date
ZA201604560B true ZA201604560B (en) 2019-01-30

Family

ID=52394405

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2016/04560A ZA201604560B (en) 2014-01-07 2016-07-05 Heterocyclic modulators of lipid synthesis for use against cancer and viral infections

Country Status (16)

Country Link
US (1) US9994550B2 (enExample)
EP (1) EP3092232B1 (enExample)
JP (1) JP6522007B2 (enExample)
KR (1) KR102335142B1 (enExample)
CN (1) CN105980376B (enExample)
AU (1) AU2015204907B2 (enExample)
BR (1) BR112016015879B1 (enExample)
CA (1) CA2935767C (enExample)
ES (1) ES2913858T3 (enExample)
IL (1) IL246463B (enExample)
MX (1) MX384392B (enExample)
NZ (1) NZ721780A (enExample)
RU (1) RU2766087C2 (enExample)
SG (1) SG11201605422TA (enExample)
WO (1) WO2015105860A1 (enExample)
ZA (1) ZA201604560B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170119786A1 (en) 2011-03-08 2017-05-04 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis
KR102071095B1 (ko) * 2012-07-03 2020-01-29 3-브이 바이오사이언시스, 인코포레이티드 지질 합성의 헤테로사이클릭 조절인자
ES2833454T3 (es) 2014-08-15 2021-06-15 Sagimet Biosciences Inc Inhibidor de la ácido graso sintasa para su uso en el tratamiento de un cáncer farmacorresistente
CN105181844A (zh) * 2015-09-11 2015-12-23 江苏嘉逸医药有限公司 一种高效液相色谱法测定甲苯磺酸索拉非尼含量和有关物质的方法
KR102644934B1 (ko) * 2016-11-11 2024-03-08 새지메트 바이오사이언시스, 인코포레이티드 지질 합성의 헤테로사이클릭 조절인자
WO2018111890A1 (en) * 2016-12-12 2018-06-21 Genentech, Inc. Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
CN106562961B (zh) * 2016-12-12 2017-09-01 深圳市宏辉浩医药科技有限公司 一种治疗脑梗塞的药物组合物
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2025086054A1 (zh) * 2023-10-23 2025-05-01 歌礼生物科技(杭州)有限公司 一种包含苯甲腈衍生物的药物组合物
AU2024395542A1 (en) 2023-12-07 2026-05-28 Böse Pharmaceuticals Ab Sulfonamide derivatives and use thereof in the treatment of cryptosporidium infections

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
DE69418699T2 (de) 1993-01-11 1999-09-30 Dana-Farber Cancer Institute, Boston Induktion der antworten zytotoxischer t-lymphozyten
RU2419612C2 (ru) * 2003-12-23 2011-05-27 Астекс Терапьютикс Лимитед Производные пиразола в качестве модуляторов протеинкиназы
WO2008075077A1 (en) 2006-12-21 2008-06-26 Astrazeneca Ab Piperidine derivatives for the treatment of obesity
TW200833663A (en) * 2006-12-21 2008-08-16 Astrazeneca Ab Therapeutic agents
TW200831092A (en) 2006-12-21 2008-08-01 Astrazeneca Ab Therapeutic agents
LT2683244T (lt) * 2011-03-08 2017-04-10 3-V Biosciences, Inc. Lipidų sintezės heterocikliniai moduliatoriai
TWI522348B (zh) * 2011-03-08 2016-02-21 3 V生物科技公司 脂質合成之雜環調節劑
KR102071095B1 (ko) 2012-07-03 2020-01-29 3-브이 바이오사이언시스, 인코포레이티드 지질 합성의 헤테로사이클릭 조절인자

Also Published As

Publication number Publication date
NZ721780A (en) 2022-01-28
IL246463A0 (en) 2016-08-31
SG11201605422TA (en) 2016-07-28
IL246463B (en) 2022-04-01
CA2935767A1 (en) 2015-07-16
RU2016127634A3 (enExample) 2019-06-17
CA2935767C (en) 2023-01-31
CN105980376B (zh) 2019-03-22
KR20160105416A (ko) 2016-09-06
US9994550B2 (en) 2018-06-12
WO2015105860A1 (en) 2015-07-16
US20160326141A1 (en) 2016-11-10
WO2015105860A9 (en) 2016-02-04
AU2015204907A1 (en) 2016-07-21
RU2766087C2 (ru) 2022-02-07
JP2017502083A (ja) 2017-01-19
CN105980376A (zh) 2016-09-28
RU2016127634A (ru) 2018-02-09
EP3092232B1 (en) 2022-03-09
AU2015204907B2 (en) 2018-08-02
KR102335142B1 (ko) 2021-12-06
EP3092232A1 (en) 2016-11-16
JP6522007B2 (ja) 2019-05-29
MX384392B (es) 2025-03-14
MX2016008841A (es) 2016-10-13
BR112016015879B1 (pt) 2022-06-14
BR112016015879A2 (enExample) 2017-08-08
ES2913858T3 (es) 2022-06-06

Similar Documents

Publication Publication Date Title
IL259421B (en) ror - gamma modulators
IL258013A (en) Modulators of kras expression
IL246463A0 (en) Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
SG11201706729SA (en) Derivatives of sobetirome
EP3140310A4 (en) Synthesis of boronate salts and uses thereof
IL266505A (en) Heterocyclic modulators of lipid synthesis
EP3099800A4 (en) Expression and purification of crm197 and related proteins
IL251477A0 (en) Anti-ang2 antibodies and methods of use
SMT202100551T1 (it) Derivati di sobetirome
GB201621707D0 (en) Synthesis and use of amino lipids
EP3179994A4 (en) Modified mito-metformin compounds and methods of synthesis and use thereof
IL248391A0 (en) Methods for using anti-ang2 antibodies
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
SG11201701803XA (en) Stabilized adrenomedullin derivatives and use thereof
IL249434B (en) Use of active negative modulators of erythropoietin for treatment
PL3174849T3 (pl) Synteza pochodnych pirolidyny
SG11201609739UA (en) Derivatives of dolaproine-dolaisoleuine peptides
ZA201701976B (en) Synthesis of ent-progesterone and intermediates thereof
PL3143032T3 (pl) Nowe pochodne oksazafosforyn i ich zastosowania terapeutyczne
EP3170823A4 (en) One class of pyrazolone compounds and use thereof
TWM476518U (en) Backplate of backpack
ZA201704416B (en) Heterocyclylalkyne derivatives and their use as modulators of mglur5 receptors
HK40015026A (en) Heterocyclic modulators of lipid synthesis
TWM532871U (en) Structure of medicine grinder
EP3212202A4 (en) Use of therapeutic agents